|
1
|
Daoudaki M and Fouzas I: Hepatocellular
carcinoma. Wien Med Wochenschr. 164:450–455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu CY, Chen KF and Chen PJ: Treatment of
liver cancer. Cold Spring Harb Perspect Med. 5:a0215352015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Altekruse SF, McGlynn KA, Dickie LA and
Kleiner DE: Hepatocellular carcinoma confirmation, treatment and
survival in surveillance, epidemiology and end results registries,
1992–2008. Hepatology. 55:476–482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fong ZV and Tanabe KK: The clinical
management of hepatocellular carcinoma in the United States, Europe
and Asia: A comprehensive and evidence-based comparison and review.
Cancer. 120:2824–2838. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Oka H, Tamori A, Kuroki T, Kobayashi K and
Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic
patients monitored for development of hepatocellular carcinoma.
Hepatology. 19:61–66. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen J, Wang A, Wang Q, Gurvich I, Siegel
AB, Remotti H and Santella RM: Exploration of genome-wide
circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a
potential biomarker. Cancer Epidemiol Biomarkers Prev.
22:2364–2373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qi XS, Guo XZ, Han GH, Li HY and Chen J:
MET inhibitors for treatment of advanced hepatocellular carcinoma:
A review. World J Gastroenterol. 21:5445–5453. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harding JJ and Abou-Alfa GK: Treating
advanced hepatocellular carcinoma: How to get out of first gear.
Cancer. 120:3122–3130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hefaiedh R, Elloumi H, Ouakaa A, Elloumi
H, Kochlef A, Gargouri D, Kilani A, Romani M, Kharrat J and Ghorbel
A: Management of the hepatocellular carcinoma. Tunis Med.
87:721–725. 2009.PubMed/NCBI
|
|
12
|
Lau WY and Lai EC: The current role of
radiofrequency ablation in the management of hepatocellular
carcinoma: A systematic review. Ann Surg. 249:20–25. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang JX, Rastetter RH and Wilhelm D:
Non-coding RNAs: An Introduction. Adv Exp Med Biol. 886:13–32.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Beermann J, Piccoli MT, Viereck J and Thum
T: Non-coding RNAs in development and disease: Background,
mechanisms and therapeutic approaches. Physiol Rev. 96:1297–1325.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peschansky VJ and Wahlestedt C: Non-coding
RNAs as direct and indirect modulators of epigenetic regulation.
Epigenetics. 9:3–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kovaříková A, Héžová R, Srovnal J,
Rédová-Lojová M and Slabý O: The role of microRNAs in molecular
pathology of esophageal cancer and their potential usage in
clinical oncology. Klin Onkol. 27:87–96. 2014.(In Czech).
View Article : Google Scholar
|
|
19
|
Ono K: Regulation of lipid metabolism by
miRNAs and transcription factors. Seikagaku. 87:733–735. 2015.(In
Japanese). PubMed/NCBI
|
|
20
|
Yan J, Jiang JY, Meng XN, Xiu YL and Zong
ZH: MiR-23b targets cyclin G1 and suppresses ovarian cancer
tumorigenesis and progression. J Exp Clin Cancer Res. 35:312016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grossi I, Arici B, Portolani N, De Petro G
and Salvi A: Clinical and biological significance of miR-23b and
miR-193a in human hepatocellular carcinoma. Oncotarget.
8:6955–6969. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshizaki A, Nakayama T, Yamazumi K,
Yakata Y, Taba M and Sekine I: Expression of interleukin (IL)-11
and IL-11 receptor in human colorectal adenocarcinoma: IL-11
up-regulation of the invasive and proliferative activity of human
colorectal carcinoma cells. Int J Oncol. 29:869–876.
2006.PubMed/NCBI
|
|
23
|
Nakayama T, Yoshizaki A, Izumida S,
Suehiro T, Miura S, Uemura T, Yakata Y, Shichijo K, Yamashita S and
Sekin I: Expression of interleukin-11 (IL-11) and IL-11 receptor
alpha in human gastric carcinoma and IL-11 upregulates the invasive
activity of human gastric carcinoma cells. Int J Oncol. 30:825–833.
2007.PubMed/NCBI
|
|
24
|
Lay V, Yap J, Sonderegger S and
Dimitriadis E: Interleukin 11 regulates endometrial cancer cell
adhesion and migration via STAT3. Int J Oncol. 41:759–764. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ayub A, Ashfaq UA and Haque A: HBV induced
HCC: Major risk factors from genetic to molecular level. Biomed Res
Int. 2013:8104612013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Parkin DM: The global health burden of
infection-associated cancers in the year. Int J Cancer.
118:3030–3044. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sanyal A, Poklepovic A, Moyneur E and
Barghout V: Population-based risk factors and resource utilization
for HCC: US perspective. Curr Med Res Opin. 26:2183–2191. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Banaudha K, Kaliszewski M, Korolnek T,
Florea L, Yeung ML, Jeang KT and Kumar A: MicroRNA silencing of
tumor suppressor DLC-1 promotes efficient hepatitis C virus
replication in primary human hepatocytes. Hepatology. 53:53–61.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Houzet L, Yeung ML, de Lame V, Desai D,
Smith SM and Jeang KT: MicroRNA profile changes in human
immunodeficiency virus type 1 (HIV-1) seropositive individuals.
Retrovirology. 5:1182008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pedersen IM, Cheng G, Wieland S, Volinia
S, Croce CM, Chisari FV and David M: Interferon modulation of
cellular microRNAs as an antiviral mechanism. Nature. 449:919–922.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lanford RE, Hildebrandt-Eriksen ES, Petri
A, Persson R, Lindow M, Munk ME, Kauppinen S and Ørum H:
Therapeutic silencing of microRNA-122 in primates with chronic
hepatitis C virus infection. Science. 327:198–201. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xie KL, Zhang YG, Liu J, Zeng Y and Wu H:
MicroRNAs associated with HBV infection and HBV-related HCC.
Theranostics. 4:1176–1192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ge Y, Yan X, Jin Y, Yang X, Yu X, Zhou L,
Han S, Yuan Q and Yang M: MiRNA-192 [corrected] and miRNA-204
directly suppress lncRNA HOTTIP and interrupt GLS1-mediated
glutaminolysis in hepatocellular carcinoma. PLoS Genet.
11:e10057262015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao B, Gao K, Li L, Huang Z and Lin L:
miR-184 functions as an oncogenic regulator in hepatocellular
carcinoma (HCC). Biomed Pharmacother. 68:143–148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu H, Li W, Chen C, Pei Y and Long X:
MiR-335 acts as a potential tumor suppressor miRNA via
downregulating ROCK1 expression in hepatocellular carcinoma. Tumour
Biol. 36:6313–6319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chang TC, Yu D, Lee YS, Wentzel EA, Arking
DE, West KM, Dang CV, Thomas-Tikhonenko A and Mendell JT:
Widespread microRNA repression by Myc contributes to tumorigenesis.
Nat Genet. 40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Irani S and Hussain MM: Role of
microRNA-30c in lipid metabolism, adipogenesis, cardiac remodeling
and cancer. Curr Opin Lipidol. 26:139–146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jin L, Wessely O, Marcusson EG, Ivan C,
Calin GA and Alahari SK: Prooncogenic factors miR-23b and miR-27b
are regulated by Her2/Neu, EGF and TNF-α in breast cancer. Cancer
Res. 73:2884–2896. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rice MA, Ishteiwy RA, Magani F, Udayakumar
T, Reiner T, Yates TJ, Miller P, Perez-Stable C, Rai P, Verdun R,
et al: The microRNA-23b/-27b cluster suppresses prostate cancer
metastasis via Huntingtin-interacting protein 1-related. Oncogene.
35:4752–4761. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Permyakov EA, Uversky VN and Permyakov SE:
Interleukin-11: A multifunctional cytokine with intrinsically
disordered regions. Cell Biochem Biophys. 74:285–296. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Teicher B, Ara G and Northey D:
Interaction of interleukin-11 (rhIL-11) with cytotoxic therapies in
the human HT-29 colon carcinoma. Int J Oncol. 10:1081–1085.
1997.PubMed/NCBI
|
|
45
|
Furugaki K, Moriya Y, Iwai T, Yorozu K,
Yanagisawa M, Kondoh K, Fujimoto-Ohuchi K and Mori K: Erlotinib
inhibits osteolytic bone invasion of human non-small-cell lung
cancer cell line NCI-H292. Clin Exp Metastasis. 28:649–659. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Morinaga Y, Fujita N, Ohishi K, Zhang Y
and Tsuruo T: Suppression of interleukin-11-mediated bone
resorption by cyclooxygenases inhibitors. J Cell Physiol.
175:247–254. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Buchert M, Burns CJ and Ernst M: Targeting
JAK kinase in solid tumors: Emerging opportunities and challenges.
Oncogene. 35:939–951. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zurita AJ, Troncoso P, Cardo-Vila M,
Logothetis CJ, Pasqualini R and Arap W: Combinatorial screenings in
patients: The interleukin-11 receptor alpha as a candidate target
in the progression of human prostate cancer. Cancer Res.
64:435–439. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lewis VO, Ozawa MG, Deavers MT, Wang G,
Shintani T, Arap W and Pasqualini R: The interleukin-11 receptor α
as a candidate ligand-directed target in osteosarcoma: Consistent
data from cell lines, orthotopic models and human tumor samples.
Cancer Res. 69:1995–1999. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen Q, Rabach L, Noble P, Zheng T, Lee
CG, Homer RJ and Elias JA: IL-11 receptor alpha in the pathogenesis
of IL-13-induced inflammation and remodeling. J Immunol.
174:2305–2313. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Nicoletti F, Zaccone P, Conget I, Gomis R,
Möller C, Meroni PL, Bendtzen K, Trepicchio W and Sandler S: Early
prophylaxis with recombinant human interleukin-11 prevents
spontaneous diabetes in NOD mice. Diabetes. 48:2333–2339. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lgssiar A, Hassan M, Schott-Ohly P,
Friesen N, Nicoletti F, Trepicchio WL and Gleichmann H:
Interleukin-11 inhibits NF-kappaB and AP-1 activation in islets and
prevents diabetes induced with streptozotocin in mice. Exp Biol Med
(Maywood). 229:425–436. 2004. View Article : Google Scholar : PubMed/NCBI
|
